NCT02564900 · OUTCOME

Overall Survival Among Participants With Advanced Solid Malignant Tumors (Dose Expansion Phases)

Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors · Source last updated 2024-01-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: months
Interval / dispersion: 95% Confidence Interval
Time frame: From 6 months postdose of last participant up to 3 years 5 months

What was measured

Overall survival (OS) by independent central review was defined as the time interval from the date of enrollment to the date of death from any cause. HER2-positive other solid tumors included participants with salivary/submandibular/parotid gland (8 participants), breast with HER2-mutation (2 participants), endometrial (2 participants), esophageal (2 participants), Paget's disease (2 participants), cholangiocarcinoma (1 participant), extraskeletal myxoide chondrosarcoma (1 participant), gallbladder (1 participant), pancreatic (1 participant), small intestine (1 participant), uterine cervix (1 participant) and HER2-low gastric/GEJ (1 participant who received 5.4 mg/kg) cancer.

Analysis population: OS was assessed in the Intent-to-Treat Analysis Set.

Groups in this outcome

Dose Expansion: HER2-positive Breast Cancer, 5.4 mg/kg

Participants with HER2-overexpressing breast cancer received an intravenous 5.4 mg/kg dose of DS-8201a (FL-DP1).

Dose Expansion: HER2-positive Breast Cancer, 6.4 mg/kg

Participants with HER2-overexpressing breast cancer received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).

Dose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kg

Participants with HER2-low expressing breast cancer received an intravenous 5.4 mg/kg dose of DS-8201a (FL-DP1).

Dose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kg

Participants with HER2-low expressing breast cancer received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).

Dose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kg

Participants with HER2-overexpressing gastric or gastroesophageal junction (GEJ) adenocarcinoma received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).

Dose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kg

Participants with HER2-overexpressing gastric or gastroesophageal junction (GEJ) adenocarcinoma received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).

Dose Expansion: HER2-expressing NSCLC Tumors

Participants with HER2-expressing NSCLC tumors received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).

Dose Expansion: HER2-expressing Colorectal Tumors

Participants with HER2-expressing colorectal tumors received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).

Dose Expansion: HER2-expressing Other Solid Tumors

Participants with any other HER2-expressing solid tumor other than breast or gastric or any tumor with HER2 mutation received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Dose Expansion: HER2-positive Breast Cancer, 5.4 mg/kg	51
Dose Expansion: HER2-positive Breast Cancer, 6.4 mg/kg	67
Dose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kg	21
Dose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kg	33
Dose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kg	19
Dose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kg	25
Dose Expansion: HER2-expressing NSCLC Tumors	18
Dose Expansion: HER2-expressing Colorectal Tumors	20
Dose Expansion: HER2-expressing Other Solid Tumors	23

Reported measurements

Source class 1

Values in months · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Dose Expansion: HER2-positive Breast Cancer, 5.4 mg/kg	NA	Not reported	NA	NA	Lack of median value is due to less than 50% of the participants experiencing the event. In a Kaplan-Meier analysis, the curve would never fall below the 50% mark, and would continue to the largest observed censored time value.
Dose Expansion: HER2-positive Breast Cancer, 6.4 mg/kg	NA	Not reported	26.4	NA	Median and 95% confidence interval were not calculable due to insufficient number of participants with events.
Dose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kg	NA	Not reported	NA	NA	Lack of median value is due to less than 50% of the participants experiencing the event. In a Kaplan-Meier analysis, the curve would never fall below the 50% mark, and would continue to the largest observed censored time value.
Dose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kg	19.7	Not reported	12.5	29.4	Not reported
Dose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kg	18.9	Not reported	5.7	NA	Missing upper bound is related to right-censored data. Last time point censored and estimate is essentially infinity, therefore it is NA.
Dose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kg	26.2	Not reported	10.0	NA	Missing upper bound is related to right-censored data. Last time point censored and estimate is essentially infinity, therefore it is NA.
Dose Expansion: HER2-expressing NSCLC Tumors	NA	Not reported	17.3	NA	Median and 95% confidence interval were not calculable due to insufficient number of participants with events.
Dose Expansion: HER2-expressing Colorectal Tumors	15.6	Not reported	4.8	NA	Missing upper bound is related to right-censored data. Last time point censored and estimate is essentially infinity, therefore it is NA.
Dose Expansion: HER2-expressing Other Solid Tumors	23.4	Not reported	9.7	NA	Missing upper bound is related to right-censored data. Last time point censored and estimate is essentially infinity, therefore it is NA.

Complete source fields

classes

categories
measurements
comment
Lack of median value is due to less than 50% of the participants experiencing the event. In a Kaplan-Meier analysis, the curve would never fall below the 50% mark, and would continue to the largest observed censored time value.
group Id
OG000
lower Limit
NA
upper Limit
NA
value
NA
comment
Median and 95% confidence interval were not calculable due to insufficient number of participants with events.
group Id
OG001
lower Limit
26.4
upper Limit
NA
value
NA
comment
Lack of median value is due to less than 50% of the participants experiencing the event. In a Kaplan-Meier analysis, the curve would never fall below the 50% mark, and would continue to the largest observed censored time value.
group Id
OG002
lower Limit
NA
upper Limit
NA
value
NA
group Id
OG003
lower Limit
12.5
upper Limit
29.4
value
19.7
comment
Missing upper bound is related to right-censored data. Last time point censored and estimate is essentially infinity, therefore it is NA.
group Id
OG004
lower Limit
5.7
upper Limit
NA
value
18.9
comment
Missing upper bound is related to right-censored data. Last time point censored and estimate is essentially infinity, therefore it is NA.
group Id
OG005
lower Limit
10.0
upper Limit
NA
value
26.2
comment
Median and 95% confidence interval were not calculable due to insufficient number of participants with events.
group Id
OG006
lower Limit
17.3
upper Limit
NA
value
NA
comment
Missing upper bound is related to right-censored data. Last time point censored and estimate is essentially infinity, therefore it is NA.
group Id
OG007
lower Limit
4.8
upper Limit
NA
value
15.6
comment
Missing upper bound is related to right-censored data. Last time point censored and estimate is essentially infinity, therefore it is NA.
group Id
OG008
lower Limit
9.7
upper Limit
NA
value
23.4

denoms

counts
group Id
OG000
value
51
group Id
OG001
value
67
group Id
OG002
value
21
group Id
OG003
value
33
group Id
OG004
value
19
group Id
OG005
value
25
group Id
OG006
value
18
group Id
OG007
value
20
group Id
OG008
value
23
units
Participants

description

dispersion Type

95% Confidence Interval

groups

description
Participants with HER2-overexpressing breast cancer received an intravenous 5.4 mg/kg dose of DS-8201a (FL-DP1).
id
OG000
title
Dose Expansion: HER2-positive Breast Cancer, 5.4 mg/kg
description
Participants with HER2-overexpressing breast cancer received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).
id
OG001
title
Dose Expansion: HER2-positive Breast Cancer, 6.4 mg/kg
description
Participants with HER2-low expressing breast cancer received an intravenous 5.4 mg/kg dose of DS-8201a (FL-DP1).
id
OG002
title
Dose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kg
description
Participants with HER2-low expressing breast cancer received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).
id
OG003
title
Dose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kg
description
Participants with HER2-overexpressing gastric or gastroesophageal junction (GEJ) adenocarcinoma received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).
id
OG004
title
Dose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kg
description
Participants with HER2-overexpressing gastric or gastroesophageal junction (GEJ) adenocarcinoma received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).
id
OG005
title
Dose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kg
description
Participants with HER2-expressing NSCLC tumors received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).
id
OG006
title
Dose Expansion: HER2-expressing NSCLC Tumors
description
Participants with HER2-expressing colorectal tumors received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).
id
OG007
title
Dose Expansion: HER2-expressing Colorectal Tumors
description
Participants with any other HER2-expressing solid tumor other than breast or gastric or any tumor with HER2 mutation received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).
id
OG008
title
Dose Expansion: HER2-expressing Other Solid Tumors

param Type

MEDIAN

population Description

OS was assessed in the Intent-to-Treat Analysis Set.

reporting Status

POSTED

time Frame

From 6 months postdose of last participant up to 3 years 5 months

title

Overall Survival Among Participants With Advanced Solid Malignant Tumors (Dose Expansion Phases)

type

SECONDARY

unit Of Measure

months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice